A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
Status:
Completed
Trial end date:
2020-08-12
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two
different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in
hospitalized adult participants with moderate to severe COVID-19 pneumonia.